RGNT · Regentis Biomaterials Ltd.
$1.82
+0.04 (+2.25%)
At close · Jul 29
Market Cap
$9.22M
Shares
5.18M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Net Income
-$13.65M
-384.3%
FY2025
Diluted EPS
-$24.16
-1504.7%
FY2025
Operating Cash Flow
-$1.38M
-114.5%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| $6.64M | $712K | $1.13M | |
| -$6.97M | $932K | -$1.93M | |
| -$6.68M | $3.87M | -$2.2M | |
| $13.65M | -$4.8M | $4.13M | |
| -$13.65M | $4.8M | -$4.13M | |
| USD/shares | -$24.16 | $1.72 | -$24.09 |
| USD/shares | -$24.16 | $1.72 | -$24.09 |
| shares | 566.74K | 2.77M | 173.51K |
| shares | 566.74K | 2.77M | 173.51K |
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.